alpha(1)-Adrenergic receptor subtype function in fetal and adult cerebral arteries

Am J Physiol Heart Circ Physiol. 2010 Jun;298(6):H1797-806. doi: 10.1152/ajpheart.00112.2010. Epub 2010 Mar 26.

Abstract

In the developing fetus, cerebral artery (CA) contractility demonstrates significant functional differences from that of the adult. This may be a consequence of differential activities of alpha(1)-adrenergic receptor (alpha(1)-AR) subtypes. Thus we tested the hypothesis that maturational differences in adrenergic-mediated CA contractility are, in part, a consequence of differential expression and/or activities of alpha(1)-AR subtypes. In CA from fetal ( approximately 140 days) and nonpregnant adult sheep, we used wire myography and imaging, with simultaneous measurement of tension and intracellular Ca(2+) concentration ([Ca(2+)](i)), radioimmunoassay, and Western immunoblots to examine phenylephrine (Phe)-induced contractile responses. The alpha(1A)-AR antagonists (5-MU and WB-4101) completely inhibited Phe-induced contraction in adult but not fetal CA; however, [Ca(2+)](i) increase was reduced significantly in both age groups. The alpha(1D)-AR antagonist (BMY-7378) blocked both Phe-induced contractions and Ca(2+) responses to a significantly greater extent in adult compared with fetal CA. In both age groups, inhibition of alpha(1A)-AR and alpha(1B)-AR, but not alpha(1D)-AR, significantly reduced inositol 1,4,5-trisphosphate responses to Phe. Western immunoblots demonstrated that the alpha(1)-AR subtype expression was only approximately 20% in fetal CA compared with the adult. Moreover, in fetal CA, the alpha(1D)-AR was expressed significantly greater than the other two subtypes. Also, in fetal but not adult CA, Phe induced a significant increase in activated ERK1/2; this increase in phosphorylated ERK was blocked by alpha(1B)-AR (CEC) and alpha(1D)-AR (BMY-7378) inhibitors, but not by alpha(1A)-AR inhibitors (5-MU or WB-4101). In conclusion, in the fetal CA, alpha(1B)-AR and alpha(1D)-AR subtypes play a key role in contractile response as well as in ERK activation. We speculate that in fetal CA alpha(1B)-AR and alpha(1D)-AR subtypes may be a critical factor associated with cerebrovascular growth and function.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adrenergic alpha-Antagonists / pharmacology
  • Animals
  • Cell Communication / physiology
  • Cerebral Arteries / drug effects
  • Cerebral Arteries / embryology*
  • Cerebral Arteries / physiology*
  • Dioxanes / pharmacology
  • Extracellular Signal-Regulated MAP Kinases / physiology
  • Fetus / blood supply*
  • Inositol 1,4,5-Trisphosphate / pharmacology
  • Models, Animal
  • Norepinephrine / pharmacology
  • Piperazines / pharmacology
  • Receptors, Adrenergic, alpha-1 / classification*
  • Receptors, Adrenergic, alpha-1 / drug effects
  • Receptors, Adrenergic, alpha-1 / physiology*
  • Regional Blood Flow / drug effects
  • Regional Blood Flow / physiology*
  • Sheep
  • Vasoconstriction / drug effects
  • Vasoconstrictor Agents / pharmacology

Substances

  • Adrenergic alpha-Antagonists
  • Dioxanes
  • Piperazines
  • Receptors, Adrenergic, alpha-1
  • Vasoconstrictor Agents
  • Inositol 1,4,5-Trisphosphate
  • (2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane
  • Extracellular Signal-Regulated MAP Kinases
  • BMY 7378
  • Norepinephrine